Stakeholder interest is high in progressing beyond the current targeting criteria and requirement for an annual comprehensive medication review, but a significant regulatory hurdle exists. Beyond this hurdle, beneficiary involvement and...
Stakeholder interest is high in progressing beyond the current targeting criteria and requirement for an annual comprehensive medication review, but a significant regulatory hurdle exists. Beyond this hurdle, beneficiary involvement and...
Stakeholder interest is high in...